PERNIASPOPConsumer Discretionary

Purple Style Labs Limited

Speciality Retail · ISIN INE0I1B01016 · BSE 544901 · NSE EQ · FV ₹10
Last price
₹570
-0.97%today
What this company does

Purple Style Labs Limited operates in Speciality Retail, part of the Consumer Discretionary sector.

Is this company doing well?

We don't have enough financial data on this company yet to summarise its health. Try one of the companies marked Full data in search.

Key ratios · latest quarter + price
₹570 -0.97%
latest close · 2026-09-11
52-wk low ₹5165 sessions so far52-wk high ₹589
More figures
Market cap
Book value
EPS
latest quarter
Net debt
Enterprise value
EBITDA
EBIT
Operating margin
Return on assets
Earnings yield
P/S
Sales / share
Tax rate
Face value
Working capital
Current assets
Current liabilities

P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-11.

Worth vs price · from the exchange filings
not investment advice
Hard to value confidentlyLow confidence
We haven't parsed this company's annual profit history yet — common for banks and insurers, whose results file in a different format — so we can't value it off earnings.

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

Peer comparison
Speciality Retail · by market value
CompanyPriceMarket capP/E
Trent Limited₹2,802₹1.49 L cr72.0
Lenskart Solutions Limited₹682₹1.19 L cr133.2
Arvind Fashions Limited₹447₹16,437 cr148.8
Vedant Fashions Limited₹582₹14,146 cr52.9
Aditya Birla Lifestyle Brands Limited₹84₹10,205 cr87.1
Aditya Vision Limited₹616₹7,958 cr25.8
V2 Retail Limited₹218₹7,949 cr47.4
Aditya Birla Fashion and Retail Limited₹50₹6,156 cr
Shankara Buildpro Limited₹1,253₹3,037 cr21.2
Same industry · latest reported numbers · not a recommendation.
How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.